Nevro (NYSE: NVRO) reported Q3 EPS of ($0.58), $0.27 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $100.16 million versus the consensus estimate of $92.27 million.

"Our strong third quarter 2019 financial results demonstrate our continued improvement in commercial focus and execution across the organization. In the U.S., we saw an 18% year-over-year increase in both patient trial procedures and permanent implant procedures," said D. Keith Grossman, Chairman, CEO and President. "Yesterday we announced the commercial launch of our groundbreaking Senza Omnia system, the only SCS system that offers HF10 therapy in addition to all other SCS frequencies, as well as frequency pairing with HF10. We're excited by the early customer feedback we've received, and we believe this new product introduction, along with our ongoing operational initiatives, positions us for continued growth in 2020 and beyond."

For earnings history and earnings-related data on Nevro (NVRO) click here.